Skip to content

Author

A. Takashima

We have 2 of 367 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.

Fruquintinib demonstrated feasible effectiveness and manageable toxicity in Japanese patients with mCRC and proteinuria was a major determinant of treatment feasibility and frequently led to early dose modification.

Shohei Udagawa, Chihiro Ishizuka, H. Osumi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.